Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.41 |
| ▸ | KRAS | P01116 | 9/20 | 0.41 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340576 | 0.92 | AKT1 (0.41) | KITKRASAKT1HTTPDGFRB | |
| SCHEMBL19296798 | 0.90 | KIT (0.44) | KITKRASAKT1PDGFRBPDGFRA | |
| SCHEMBL16637078 | 0.89 | KIT (0.41) | KITKRASAKT1PDGFRBPDGFRA | |
| SCHEMBL20340564 | 0.89 | KIT (0.48) | KITPDGFRBPDGFRA | |
| SCHEMBL20340565 | 0.89 | KIT (0.48) | KITPDGFRBPDGFRA | |
| SCHEMBL16646948 | 0.86 | KRAS (0.51) | KRAS | |
| SCHEMBL16636857 | 0.86 | KRAS (0.51) | KRAS | |
| SCHEMBL16636858 | 0.86 | KRAS (0.51) | KRAS | |
| SCHEMBL29765783 | 0.86 | KRAS (0.51) | KRAS | |
| SCHEMBL29765906 | 0.86 | KRAS (0.51) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | KIT 1512/4885KRAS 1/4885AKT1 415/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | KIT 1512/4885KRAS 1/4885AKT1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.